| Literature DB >> 36141929 |
Hana Kim1, I Seul Jeong1, Mi-Kyoung Cho1.
Abstract
Herein, we performed a meta-analysis evaluating the effects of treatment adherence enhancement programs on treatment adherence and secondary outcomes for hemodialysis patients. Twenty-five Korean and international articles published prior to 31 March 2022 were selected following the PRISMA and Cochrane Systematic Review guidelines. We calculated summary effect sizes, conducted homogeneity and heterogeneity testing, constructed a funnel plot, and performed Egger's regression test, Begg's test, trim-and-fill method, subgroup analyses, and univariate meta-regression. The overall effect of treatment adherence enhancement programs for hemodialysis patients was statistically significant (Hedges' g = 1.10, 95% CI: 0.77, 1.43). On performing subgroup analysis to determine the cause of effect size heterogeneity, statistically significant moderating effects were found for a range of input variables (Asian countries, study centers, sample size, study design, intervention types, number of sessions, quality assessment scores, funding, and evidence-based interventions). On univariate meta-regression, larger synthesized effect sizes were found for a range of study characteristics (Asian populations, single-center studies, studies with <70 participants, quasi-experimental studies, educational interventions, studies with >12 sessions, studies with quality assessment scores above the mean, unfunded studies, and non-theory-based interventions). Our results provide evidence-based information for enhancing program efficacy when designing treatment adherence enhancement programs for hemodialysis patients.Entities:
Keywords: hemodialysis; meta-analysis; systematic review; treatment adherence and compliance
Mesh:
Year: 2022 PMID: 36141929 PMCID: PMC9517018 DOI: 10.3390/ijerph191811657
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Study eligibility criteria.
| Inclusion Criteria | Exclusion Criteria | |
|---|---|---|
| Participants | Adults aged >18 years on hemodialysis for chronic renal failure. | Enrolled study participants participated in other studies that may affect treatment adherence. |
| Studies published through 31 March 2022. | ||
| Intervention | Intervention programs related to treatment compliance or treatment adherence (medication, fluid, diet, or dialysis treatment). | --- |
| Studies report means, standard deviations, and concrete sample sizes. | ||
| Control | Usual or standard treatment, comparative experiments. | --- |
| Outcomes | Primary outcome: treatment compliance or treatment adherence indirectly measured through self-report questionnaires. When serial interventions were performed, only the effects measured at the end of the intervention were used for analysis. | Studies that did not measure treatment adherence or treatment compliance. |
| Secondary outcomes: inter-dialytic weight gain, serum phosphorus levels, and serum potassium levels. When serial interventions were performed, only effects measured at the end of the intervention period were used for analysis. | Studies that measured non-compliance or treatment non-adherence. | |
| Study design | Quasi-experimental studies or RCTs. | Non-quasi-experimental studies or non-RCTs. |
| For quasi-experimental studies, single-group comparative studies were excluded. |
Abbreviations: RCTs, randomized controlled trials.
Figure 1Study extraction process.
Descriptive summary of the included studies.
| No | Author | Year | Country | Center | Participants | Participants Characteristics | Design | Intervention | Characteristics of Interventions | Outcome Variables | Quality Score | Funding | Theory-Based |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vardanjani et al. [ | 2015 | Iran | 1 | N = 66 | Age ≥ 18 years | RCT | Education program (individual, feedback) | 8 sessions | Adherence (ESRD-AQ), IDWG, K, P, Na, Cr, BUN, Ca, Alb, alkaline phosphatase, Hb | 8 | Yes | No |
| 2 | Rodrigues et al. [ | 2019 | India | 1 | N = 100 | Age ≥ 18 years | RCT | Education & counseling program | Pharmacist | Adherence (medication adherence), medication knowledge | 6 | No | No |
| 3 | Park & Kim [ | 2019 | Korea | 1 | N = 84 | 19 ≤ age ≤ 60 years | Quasi-E | Integrated self-management program (face-to-face counseling and education (twice per month), use of mobile applications, questions about hemodialysis self-management) | 4 sessions | Adherence, IDWG, K, P, self-efficacy, treatment | 8 | No | Yes |
| 4 | Alikari et al. [ | 2018 | Greece | 1 | N = 50 | 18 ≤ age ≤ 65 years | Quasi-E | Educational intervention & booklet (Dialysis. Answers to common questions) | One-time personalized educational intervention (face-to-face) | Adherence (medication adherence: GR-SMAQ-HD), medication knowledge (KDQ), QoL (MVQoLI-15) | 6 | No | No |
| 5 | Griva et al. [ | 2018 | Singapore | 14 | N = 235 | Age ≥ 21 years | RCT | Self-management intervention (fluid intake, diet, medication) | 4 sessions | Adherence (self-reported adherence), IDWG, K, P | 11 | Yes | Yes |
| 6 | Yun & Choi [ | 2016 | Korea | 1 | N = 62 | Age ≥ 20 years | Quasi-E | Dietary self-efficacy program | 8 sessions | Adherence (dietary adherence), IDWG, K, P, | 8 | No | Yes |
| 7 | Zhianfar et al. [ | 2020 | Iran | 1 | N = 70 | Age ≥ 18 years | RCT | Multifaceted educational intervention (education, CBT, social support) | 8 sessions | Adherence (ESRD-AQ), IDWG, nursing care satisfaction (PSNCQQ), QOL (WHOQOL-SF), perceived social support (MSPSS), depression (BDI-SF) | 7 | Yes | No |
| 8 | Arad et al. [ | 2021 | Iran | 1 | N = 66 | 20 ≤ age ≤ 65 years | RCT | Education program and nurse-led telephone follow-up (including SMS) | 24 sessions (twice a week) | Adherence (ESRD-AQ), K, P, Na, Cr, BUN, Ca, Alb, Hb, iron, normalized protein catabolic rate (nPCR), and Kt/V | 8 | No | No |
| 9 | Baser & Mollaoglu [ | 2019 | Turkey | 1 | N = 78 | Age ≥ 18 years | Quasi-E | Education program (nutrition education booklet for dialysis patients) | 4 sessions | Adherence (FCHPS), | 8 | No | No |
| 10 | Parvan et al. [ | 2015 | Iran | 1 | N = 58 | Age ≥ 18 years | RCT | Education program (knowledge about the disease, medication, fluid restriction, diet) | E1—pamphlet, E2—2 consecutive sessions | Adherence (MOS), hemodialysis knowledge (CHeKS) | 7 | Yes | No |
| 11 | Kim et al. [ | 2015 | Korea | 1 | N = 40 | Mean age: 62.78 (10.64) years (E = 64.20 [9.47], C = 61.35 [11.77]) | Quasi-E | Education program (knowledge about the disease, exercise, medication, diet, weight control, pain, and sexuality) | 8 sessions (once a week) | Adherence (compliance) IDWG, K, P, knowledge, Alb, Hb, Kt/V | 8 | Yes | No |
| 12 | Wileman et al. [ | 2016 | UK | 3 | N = 89 | Mean age (years) (E = 62.8 [14.9], C = 58.2 [16.0]) | RCT | Self-affirmation intervention | Nephrologist | Adherence, IDWG | 10 | No | Yes |
| 13 | Chang et al. [ | 2021 | Korea | 3 | N = 84 | Age ≥ 20 years | Quasi-E | auricular acupressure and a fluid-restriction adherence program | 6 sessions (once a week) | Adherence (fluid control), IDWG, DQOL, salivary flowrate | 8 | Yes | Yes |
| 14 | Ok & Kutlu [ | 2021 | Turkey | 1 | N = 60 | 18 ≤ age ≤ 65 years | RCT | Motivation interviewing (determine the cause of patient’s adherence problems, boost the motivation of change, discuss change, evaluate) | 4 sessions | Adherence (ESRD-AQ), K, P, SF-36, daily weight gain or fluid intake, Alb, Kt/V | 9 | Yes | No |
| 15 | So et al. [ | 2006 | Korea | 1 | N = 60 | 20 ≤ age ≤ 7 years | Quasi-E | Drug education program (knowledge, enhance medication adherence) | 4 sessions | Adherence (medical compliance), medication knowledge | 7 | No | No |
| 16 | Lim et al. [ | 2018 | Korea | 1 | N = 70 | Age ≥ 18 years | RCT | Education (low-phosphate diet and phosphate binder intake) | One-time personalized educational intervention (face-to-face) | Adherence (medication adherence; MMAS-8), P, number of patients who reached the goal of a calcium-phosphate product lower than 55, dietary phosphate intake, PG-SGA (phosphate intake, acknowledge of phosphate binder, the bioequivalent dosage of phosphate binder) | 9 | No | No |
| 17 | Mateti et al. [ | 2018 | India | 3 | N(academic) = 83 (E = 4, C = 41) | 18 ≤ age ≤ 75 year | RCT | Pharmaceutical education & motivation intervention | 52 weeks | Adherence (medication adherence; MMAS-8), IDWG, Hb, BP | 9 | No | No |
| 18 | Klein et al. [ | 2017 | USA | 6 | N = 118 | Age ≥ 18 years | RCT | Education & counseling program | 12 sessions | Adherence (medication adherence; MMAS-4), IDWG, BP self-efficacy, BP control, sodium intake | 7 | Yes | Yes |
| 19 | Kim & Yoo [ | 2006 | Korea | 1 | N = 40 | Age ≥ 20 years | Quasi-E | Education program | 6 sessions | Adherence (compliance), K, P, knowledge, Cr, BUN, Alb | 8 | No | No |
| 20 | Kim & Han [ | 2016 | Korea | 1 | N = 100 | Age ≥ 19 years | Quasi-E | Education program (individualized diet education) | 6 sessions | Adherence (compliance), knowledge | 7 | No | No |
| 21 | An [ | 2009 | Korea | 4 | N = 96 | Age ≤ 70 years | Quasi-E | Education program | 12 sessions | Adherence (compliance), IDWG, K, P, Alb, Hb, Hct, protein, cholesterol, transferrin | 8 | Yes | No |
| 22 | Kim et al. [ | 2014 | Korea | 1 | N = 41 | Age ≥ 19 years | Quasi-E | Education program | 8 sessions | Adherence (compliance), IDWG, K, P | 7 | Yes | No |
| 23 | Lee et al. [ | 2009 | Korea | 1 | N = 41 | Mean age (years) E = 58.6 (10.2), C = 56.5 (14.3) | Quasi-E | Education &counseling program | 18 sessions | Adherence (compliance), knowledge, IDWG, K, P | 8 | No | No |
| 24 | Seyyedrasooli et al. [ | 2013 | Iran | 1 | N = 71 | Age ≥ 18 years | RCT | Education program | 6 sessions | Adherence (ESRD-AQ) | 6 | No | No |
| 25 | Hashemi et al. [ | 2018 | Iran | 1 | N = 98 | Mean age (years) E = 62.33 (14.22), C = 59.50 (16.14) | RCT | Education &counseling & training program | 13~15 sessions | Adherence (ESRD-AQ) | 9 | No | No |
Abbreviations: Alb, albumin; BDI-SF, the Beck Depression Inventory-Short Form; BP, blood pressure; BUN, blood urea nitrogen; C, control group; Ca, Calcium; CHeKS, Chronic Hemodialysis Knowledge Survey; Cr, Creatinine; DDFQ, The dialysis diet and fluid non-adherence questionnaire; DQOL, Diabetes Quality of Life; E, experimental group; E1, experimental group 1; E2, experimental group 2; ESRD, end-stage renal disease; ESRD-AQ, End-Stage Renal Disease Adherence Questionnaire; FCHPS, the Fluid Control in Hemodialysis Patients Scale; F/U, Follow up; GR-SMAQ-HD, Greek version of Simplified Medication Adherence Questionnaire for patients undergoing hemodialysis; Hb, hemoglobin; Hct, hematocrit; HD, hemodialysis; HRQoL, the health-related quality of life instrument; IDWG, Interdialytic Weight Gain; K, potassium; KDQ, Kidney Disease Questionnaire; Kt/V, a number used to quantify hemodialysis treatment adequacy; MMAS-4, The 4-item Morisky Medication Adherence Scale; MMAS-8, The 8-item Morisky Medication Adherence Scale; MOS, Medical Outcomes Study; MSPSS, Multidimensional Scale of Perceived Social Support; MVQoLI-15, the Missoula-VITAS Quality of Life Index; N, number of subjects; Na, sodium; P, phosphorus; PG-SGA, Patient-Generated Subjective Global Assessment; PSNCQQ, Patient Satisfaction with Nursing Care Quality Questionnaire; QoL, Quality of Life; Quasi-E, quasi-experimental studies; RCT, randomized controlled trials; SF-36, Short Form 36; SMS, short message service; UF, ultrafiltration; UK, United Kingdom; USA, United states of America; WHOQOL-SF: World Health Organization Quality of Life Assessment-Short Form Health Survey.
Quality assessment of the included studies.
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 6 |
| 5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 11 |
| 7 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| 8 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| 10 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| 12 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 10 |
| 14 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 9 |
| 16 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 9 |
| 17 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 9 |
| 18 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| 24 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 6 |
| 25 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Subtotal | 13 | 6 | 7 | 3 | 1 | 2 | 10 | 13 | 13 | 13 | 1 | 12 | 13 | 8.23 |
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||
| 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 | ||||
| 4 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 6 | ||||
| 6 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| 9 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| 11 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| 13 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 | ||||
| 15 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | ||||
| 19 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| 20 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 | ||||
| 21 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| 22 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | ||||
| 23 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||||
| Subtotal | 12 | 10 | 2 | 12 | 12 | 11 | 12 | 8 | 12 | 7.58 | ||||
Figure 2Effects of the evaluated intervention programs on treatment adherence. Duplicate removal of the number of participants in the study of [17,18,19,20]. Studies with two or more experimental groups are marked with a, b, and c for classification. N, number of subjects; ES, effect size; CI, Confidence interval; Hg, Hedge’s g.
Subgroup analysis regarding treatment adherence by study characteristics.
| Characteristics | Subgroup | K | Study ID | N | Overall ES | 95% CI | Z ( | I2 (%) | |
|---|---|---|---|---|---|---|---|---|---|
| Lower Limit | Upper Limit | ||||||||
| Location (country of publication) | East Asia | 12 | 3, 5, 6, 11, 13, 15, 16, 19, 20, 21, 22, 23 | 952 | 0.81 | 0.45 | 1.18 | 4.40 (<0.001) | 86.1 |
| West Asia | 8 | 1, 7, 8, 9, 10, 14, 24, 25 | 563 | 2.10 | 1.16 | 3.05 | 4.37 (<0.001) | 95.5 | |
| South Asia | 2 | 2, 17 | 253 | 1.06 | 0.75 | 1.37 | 6.64 (<0.001) | 22.3 | |
| Others | 3 | 4, 12, 18 | 257 | 0.26 | –0.30 | 0.83 | 0.92 (0.360) | 79.0 | |
| Study centers | 1 | 19 | 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 14, 15, 16, 19, 20, 22, 23, 24, 25 | 1251 | 1.35 | 0.87 | 1.82 | 5.56 (<0.001) | 92.9 |
| >1 | 6 | 5, 12, 13, 17, 18, 21 | 774 | 0.71 | 0.35 | 1.07 | 3.86 (<0.001) | 82.9 | |
| Subjects | <70 | 11 | 1, 4, 6, 7, 8, 11, 14, 15, 19, 22, 23 | 592 | 1.12 | 0.69 | 1.56 | 5.10 (<0.001) | 89.9 |
| ≥70 | 14 | 2, 3, 5, 9, 10, 12, 13, 16, 17, 18, 20, 21, 24, 25 | 1433 | 1.10 | 0.67 | 1.53 | 5.02 (<0.001) | 94.9 | |
| Study design | Quasi-E | 12 | 3, 4, 6, 9, 11, 13, 15, 19, 20, 21, 22, 23 | 775 | 0.97 | 0.61 | 1.33 | 5.27 (<0.001) | 83.4 |
| RCT | 13 | 1, 2, 5, 7, 8, 10, 12, 14, 16, 17, 18, 24, 25 | 1250 | 1.27 | 0.75 | 1.80 | 4.74 (<0.001) | 94.3 | |
| Interventions | Educational | 20 | 1, 2, 3, 4, 7, 8, 9, 10, 11, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 | 1496 | 1.23 | 0.83 | 1.63 | 5.98 (<0.001) | 92.2 |
| Others | 5 | 5, 6, 12, 13, 14 | 529 | 0.66 | 0.20 | 1.12 | 2.82 (0.005) | 83.6 | |
| Sessions † | ≤12 | 19 | 1, 3, 4, 5, 6, 7, 9, 10b, 11, 13, 14, 15, 16, 18, 19, 20, 21, 22, 24 | 1460 | 0.82 | 0.53 | 1.1 | 1.60 (<0.001) | 85.5 |
| >12 | 4 | 8, 17, 23, 25 | 358 | 2.94 | 1.36 | 4.51 | 3.65 (<0.001) | 96.6 | |
| Follow-up | Yes | 12 | 5, 7, 8, 11, 12, 13, 14, 16, 17, 19, 20, 23 | 1043 | 0.78 | 0.44 | 1.11 | 4.59 (<0.001) | 84.1 |
| No | 13 | 1, 2, 3, 4, 6, 9, 10, 15, 18, 21, 22, 24, 25 | 982 | 1.47 | 0.90 | 2.04 | 5.04 (<0.001) | 94.0 | |
| Quality assessment score | Below the mean | 11 | 1, 2, 4, 7, 8, 10, 15, 18, 20, 22, 24 | 796 | 0.79 | 0.40 | 1.18 | 3.97 (<0.001) | 85.6 |
| Above the mean | 14 | 3, 5, 6, 9, 11, 12, 13, 14, 16, 17, 19, 21, 23, 25 | 1229 | 1.34 | 0.85 | 1.82 | 5.40 (<0.001) | 93.3 | |
| Funding | Yes | 10 | 1, 5, 7, 10, 11, 13, 14, 18, 21, 22 | 863 | 0.68 | 0.37 | 0.98 | 4.28 (<0.001) | 80.2 |
| No | 15 | 2, 3, 4, 6, 8, 9, 12, 15, 16, 17, 19, 20, 23, 24, 25 | 1162 | 1.51 | 0.97 | 2.05 | 5.47 (<0.001) | 93.8 | |
| Theory-based | Yes | 6 | 3, 5, 6, 12, 13, 18 | 671 | 0.70 | 0.11 | 1.29 | 2.31 (0.021) | 92.4 |
| No | 19 | 1, 2, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25 | 1354 | 1.23 | 0.84 | 1.62 | 6.22 (<0.001) | 90.7 | |
† Missing data: Below the mean, ≤8.2 (RCTs), ≤7.6 (quasi-experimental studies); Above the mean, ≥8.2 (RCTs), ≥7.6 (quasi-experimental studies). Abbreviations: CI, Confidence interval; ES, Effect size; K, Number of studies; Quasi-E, Quasi-experimental study; RCT, randomized controlled trials.
Meta-regression analysis evaluating treatment adherence.
| Covariate (Ref.) | Estimate | SE | Z |
|
|---|---|---|---|---|
| Location (country of publication; Ref. = Others) | 0.74 | 0.14 | 5.42 | <0.001 |
| Asia | ||||
| Study centers (Ref. > 1) | 0.47 | 0.10 | 4.92 | <0.001 |
| 1 | ||||
| Participants (Ref. ≥ 70) | 0.42 | 0.11 | 3.90 | <0.001 |
| <70 | ||||
| Study design (Ref. = Quasi-E) | −0.21 | 0.10 | −2.22 | 0.026 |
| RCT | ||||
| Intervention (Ref. = Other) | 0.37 | 0.10 | 3.52 | <0.001 |
| Educational | ||||
| Sessions (Ref. ≤ 12) | 1.11 | 0.00 | 3.99 | <0.001 |
| >12 | ||||
| Quality assessment score (Ref. = Below the mean) | 0.23 | 0.10 | 2.43 | 0.015 |
| Above the mean | ||||
| Funding (Ref. = No) | −0.48 | 0.10 | −5.06 | <0.001 |
| Yes | ||||
| Theory-based (Ref. = No) | −0.48 | 0.10 | −4.84 | <0.001 |
| Yes |
Quasi-E, Quasi-experimental study; RCT, randomized controlled trials; Ref. = reference; SE, standard error.
Effects of the evaluated interventions on secondary outcomes.
| Variables | Number of Studies | N | Overall ES | 95% CI | Z ( | I2 (%) | |
|---|---|---|---|---|---|---|---|
| Lower Limit | Upper Limit | ||||||
| IDWG | 13 | 1186 | –0.29 | –0.52 | –0.06 | –2.48 (0.013) | 73.4 |
| P | 10 | 800 | −0.15 | –0.37 | 0.07 | –1.38 (0.170) | 56 |
| K | 9 | 730 | −0.24 | −0.64 | 0.15 | −1.20 (0.230) | 85.2 |
Abbreviations: CI, Confidence interval; ES, Effect size; IDWG, Interdialytic weight gain; K, Potassium; P, Phosphorous.
Figure 3Funnel plot (top) and trim-and-fill plot (bottom) of intervention programs and treatment adherence. Blue circles are original data, gray circles are imputed filled values. Hg, Hedges’ g.
Publication bias test evaluating intervention programs and treatment adherence.
| Publication Bias Test | Coefficient | SE | 95% CI | Z |
| ||
|---|---|---|---|---|---|---|---|
| Lower Limit | Upper Limit | ||||||
| Egger’s regression test | Intercept | 7.46 | 1.69 | 4.15 | 10.76 | 4.42 | <0.001 |
| Slope | −1.11 | 0.45 | −1.98 | −0.24 | −2.49 | 0.013 | |
| Tau-b | Ties | Z |
| ||||
| Begg’s test | Standard | 0.40 | 31 | 3.18 | 0.001 | ||
| Corrected | 0.40 | 31 | 3.16 | 0.002 | |||
| Hg | 95% CI | ||||||
| Lower limit | Upper limit | ||||||
| Trim-and-fill | Original | 1.10 | 0.77 | 1.43 | |||
| Trim-and-fill | 0.50 | 0.41 | 0.58 | ||||
CI, Confidence interval; Hg, Hedges’ g; SE, standard error.